Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT ID: NCT04267848

The ALCHEMIST trial is a clinical study looking at whether adding a drug called pembrolizumab, which is a type of immunotherapy, to standard chemotherapy can improve treatment outcomes for patients...

Recruiting

Phase: PHASE3 Conditions: Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 +4 more

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT ID: NCT04269902

**Summary of the EVOLVE CLL/SLL Study** The EVOLVE CLL/SLL study is a clinical trial designed to find out if starting treatment for high-risk chronic lymphocytic leukemia (CLL) or small lymphocyti...

Recruiting

Phase: PHASE3 Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT ID: NCT05882877

This clinical trial is studying a medication called rocatinlimab to see how safe it is and how well it works for people aged 12 and older who have moderate to severe atopic dermatitis, which is a t...

Recruiting

Phase: PHASE3 Conditions: Atopic Dermatitis

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT ID: NCT06646276

This clinical trial, called TIGOS, is studying a new treatment for people with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The researchers want to compare two treatment combinations: one that...

Recruiting

Phase: PHASE3 Conditions: Extensive-Stage Small Cell Lung Cancer

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT ID: NCT03866382

This clinical trial is investigating how well three medications—cabozantinib, nivolumab, and ipilimumab—work together to treat patients with rare genitourinary tumors that have spread to other part...

Recruiting

Phase: PHASE2 Conditions: Stage IVB Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 +43 more

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

NCT ID: NCT04181060

This clinical trial is studying the effects of two treatments for patients with advanced non-small cell lung cancer that has a specific gene change called an EGFR mutation. Researchers want to find...

Recruiting

Phase: PHASE3 Conditions: Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8 +3 more

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

NCT ID: NCT04548752

This clinical trial is exploring whether combining an immunotherapy drug called pembrolizumab with a cancer treatment called olaparib can work better than olaparib alone for patients with metastati...

Recruiting

Phase: PHASE2 Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT ID: NCT04579224

This clinical trial is looking at a new treatment for patients with metastatic urothelial cancer, which is a type of cancer that affects the bladder and other parts of the urinary system. Specifica...

Recruiting

Phase: PHASE3 Conditions: Metastatic Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8 +3 more

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT ID: NCT04858334

The APOLLO trial is studying the effects of a medication called olaparib in patients who have had surgery for pancreatic cancer and have specific genetic mutations (in genes called BRCA1, BRCA2, or...

Recruiting

Phase: PHASE2 Conditions: Resectable Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma +5 more

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT ID: NCT05889182

This clinical trial is studying a medication called upadacitinib to see how effective and safe it is for treating moderate to severe hidradenitis suppurativa (HS) in adults and adolescents who have...

Recruiting

Phase: PHASE3 Conditions: Hidradenitis Suppurativa

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT ID: NCT05125302

This clinical trial is studying a medication called ubrogepant to see how safe and effective it is for treating migraines in children and adolescents aged 6 to 17 years. Migraines can cause severe ...

Recruiting

Phase: PHASE3 Conditions: Migraine

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

NCT ID: NCT03609216

This clinical trial is looking at how well two chemotherapy drugs, gemcitabine and cisplatin, work for treating patients with a type of bladder cancer called muscle-invasive urothelial carcinoma. T...

Recruiting

Phase: PHASE2 Conditions: Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma +1 more

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT ID: NCT06455202

This clinical trial is studying a new treatment called barzolvolimab for adults suffering from Chronic Spontaneous Urticaria (CSU), which is a condition where people experience itchy hives without ...

Recruiting

Phase: PHASE3 Conditions: Chronic Spontaneous Urticaria

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

NCT ID: NCT06548360

This clinical trial is studying a new cream called ruxolitinib to see if it is safe and effective for children with nonsegmental vitiligo, a condition where patches of skin lose their color. The tr...

Recruiting

Phase: PHASE3 Conditions: NonSegmental Vitiligo

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT ID: NCT06855498

This clinical trial is a continuation study for people who have already participated in earlier studies involving a medication called povorcitinib, which is being tested for a skin condition known ...

Recruiting

Phase: PHASE3 Conditions: Hidradenitis Suppurativa (HS)

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT ID: NCT06516952

This clinical trial is studying a new medication called povorcitinib to see how well it helps people with prurigo nodularis, a condition that causes intense itching and skin bumps. The main goal is...

Recruiting

Phase: PHASE3 Conditions: Prurigo Nodularis

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT ID: NCT05254743

This clinical trial is comparing two medications, pirtobrutinib (also known as LOXO-305) and ibrutinib, to see which one is more effective and safer for people with Chronic Lymphocytic Leukemia (CL...

Recruiting

Phase: PHASE3 Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma +2 more

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT ID: NCT05296798

This clinical trial, called the heredERA Breast Cancer study, is looking at the effectiveness and safety of a new medication called giredestrant when combined with Phesgo (which includes pertuzumab...

Recruiting

Phase: PHASE3 Conditions: Locally Advanced or Metastatic Breast Cancer

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT ID: NCT05059444

The ORACLE trial is investigating a new blood test developed by Guardant Health that looks for small pieces of cancer DNA in the blood, known as ctDNA, in patients who have been treated for early-s...

Recruiting

Conditions: Non-small Cell Lung Cancer, Renal Cell Carcinoma +14 more

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

NCT ID: NCT03937635

This clinical trial is studying how effective a combination of three medications—lenalidomide, dexamethasone, and daratumumab—are in treating patients with high-risk smoldering myeloma. Smoldering ...

Recruiting

Phase: PHASE3 Conditions: Smoldering Plasma Cell Myeloma

Main Menu

Clinical Trials in Hot Springs, Arkansas

50 Active Trials Found in Hot Springs

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma